Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;40(11):1361-1373.
doi: 10.1016/j.tibtech.2022.04.003. Epub 2022 May 7.

A hitchhiker's guide to cancer models

Karim I Budhwani  1 , Zeelu H Patel  2 , Rachael E Guenter  2 , Areesha A Charania  2
Affiliations
Review

A hitchhiker's guide to cancer models

Karim I Budhwani et al. Trends Biotechnol. 2022 Nov.

Abstract

Cancer is a complex and uniquely personal disease. More than 1.7 million people in the United States are diagnosed with cancer every year. As the burden of cancer grows, so does the need for new, more effective therapeutics and for predictive tools to identify optimal, personalized treatment options for every patient. Cancer models that recapitulate various aspects of the disease are fundamental to making advances along the continuum of cancer treatment from benchside discoveries to bedside delivery. In this review, we use a thought experiment as a vehicle to arrive at four broad categories of cancer models and explore the strengths, weaknesses, opportunities, and threats for each category in advancing our understanding of the disease and improving treatment strategies.

Keywords: SWOT analysis; clinical translation; disease modeling; ex vivo; in silico; in vitro; in vivo; personalized medicine; precision medicine; therapeutic discovery.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Dr. Budhwani is coinventor of pending and issued patents pertaining to in vitro, ex vivo, and cancer supermodels. The other authors have no interests to declare.

Figures

Figure 1.
Figure 1.. A brief history of cancer models.
A timeline of saliant developments in cancer models over the course of the last hundred years.
Figure 2.
Figure 2.. Patient derived in vitro cultures.
From 2D cell cultures to self-assembling multicellular 3D organoids.
Figure 3.
Figure 3.. Evolution of in vivo models.
From cell line derived xenografts (CDX) to genetically engineered mouse models (GEMM).
Figure 4.
Figure 4.. From in vitro platforms to ex vivo models.
Building on strengths of in vitro platforms, ex vivo models gain momentum toward personalized medicine applications. Image adapted with permission from [76].
Figure 5.
Figure 5.. SWOT Summary.
A visual SWOT summary of each category of cancer models to highlight relative strengths and opportunities for potential innovation and synergy. Violin plots represent relative strengths of current models. For instance, broadly speaking, in vivo and ex vivo models better recapitulate tumor microenvironment (TME) whereas in vitro and in silico are more favorable from a lower cost perspective.
Figure 6.
Figure 6.. Cancer supermodels.
Next generation cancer supermodels assemble models in best-in-class configurations to harness strengths while muting weaknesses of individual contributing model categories.
See this image and copyright information in PMC

References

    1. Breasted JH (1930) The Edwin Smith Surgical Papyrus , Volume 1: Hieroglyphic Transliteration, Translation, and Commentary., 4
    1. Hajdu SI (2004) Greco-Roman thought about cancer. Cancer 100, 2048–2051 - PubMed
    1. Howlader N et al. (2019) SEER Cancer Statistics Review, 1975–2016, 1
    1. Spear BB et al. (2001) Clinical application of pharmacogenetics. Trends Mol. Med 7, 201–204 - PubMed
    1. Jakeman PG et al. (2015) Improved In Vitro Human Tumor Models for Cancer Gene Therapy. Hum. Gene Ther 26, 249–256 - PubMed

Publication types